DIFLUPREDNATE, Eylea 40 mg/mL solution for injection in pre-filled syringe, Eylea 40 mg/mL solution for injection in pre-filled syringe, 4D-150, Eylea 40 mg/mL solution for injection in pre-filled syringe, Eylea 40 mg/mL solution for injection in pre-filled syringe
4D-150-C004
Phase 3 small_molecule active
Quick answer
DIFLUPREDNATE, Eylea 40 mg/mL solution for injection in pre-filled syringe, Eylea 40 mg/mL solution for injection in pre-filled syringe, 4D-150, Eylea 40 mg/mL solution for injection in pre-filled syringe, Eylea 40 mg/mL solution for injection in pre-filled syringe for Macular neovascularization secondary to age-related macular degeneration (nAMD) is a Phase 3 program (small_molecule) at 4D Molecular Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- 4D Molecular Therapeutics
- Indication
- Macular neovascularization secondary to age-related macular degeneration (nAMD)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active